Veracyte Announces Publication of Study Supporting the Development of Envisia™ Genomic Classifier for IPF in Annals of the American Thoracic Society
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: PR Newswire
SOUTH SAN FRANCISCO, Calif., June 27, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) announced today that results of a study supporting the early development of the Envisia Genomic Classifier have been published online in the Annals of the American Thoracic Society. The genomic test, introduced commercially in October 2016, is used to improve the diagnosis of idiopathic pulmonary fibrosis (IPF), a common and severe form of interstitial lung disease (ILD), which is often challenging to diagnose without surgery.In the study, the authors demonstrated that the initial genomic classifier could accurately identify those patients with a histologic pattern of usual interstitial pneumonia (UIP) without the need for surgery. The Envisia classifier was developed using machine learning and whole-genome RNA sequencing to identify the genomic signature of UIP, a pattern whose presence is essential to IPF diagnosis, from less-invasive transbronchial biopsies (TBB) which frequently are insuffic
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines [Yahoo! Finance]Yahoo! Finance
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesBusiness Wire
- Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an "underweight" rating on the stock.MarketBeat
- Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- Veracyte, Inc. (NASDAQ: VCYT) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
VCYT
Earnings
- 2/22/24 - Miss
VCYT
Sec Filings
- 3/22/24 - Form 8-K
- 3/22/24 - Form 424B7
- 3/19/24 - Form 4
- VCYT's page on the SEC website